The FDA has approved Merck’s Enflonsia, a monoclonal antibody designed to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants.
The approval is based on data from a phase 2b/3 trial, which showed a 60.5% reduction in RSV-associated medically attended lower respiratory infections compared to placebo, according to a June 9 news release from the drugmaker.
The treatment also reduced RSV-associated hospitalizations by 84.3%. Enflonsia is administered as a single 105 mg dose, regardless of infant weight, and is designed to provide protection through a typical five-month RSV season.
The CDC’s Advisory Committee on Immunization Practices is expected to review use recommendations later this month, with distribution expected to begin before the 2025-2026 RSV season.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.